PRODUCT INFORMATION



Chartreusin

Item No. 23773

CAS Registry No.:	6377-18-0	_
Formal Name:	10-[[6-deoxy-2-O-(6-deoxy-3-O-methyl-α-D-	
	galactopyranosyl)-β-D-galactopyranosyl]oxy]-6-	HO
	hydroxy-1-methyl-benzo[h][1]benzopyrano[5,4,3-	Τ Ο O
	cde][1]benzopyran-5,12-dione	$\downarrow \downarrow \downarrow \downarrow$
Synonyms:	Antibiotic X 465A, Lambdamycin, NSC 5159	
MF:	C ₃₂ H ₃₂ O ₁₄	
FW:	640.6	
Purity:	≥98%	``H
UV/Vis.:	λ _{max} : 236, 268, 331, 400, 423 nm	
Supplied as:	A crystalline solid	
Storage:	-20°C	і он
Stability:	≥4 years	

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Chartreusin is supplied as a crystalline solid. A stock solution may be made by dissolving the chartreusin in the solvent of choice, which should be purged with an inert gas. Chartreusin is soluble in organic solvents such as acetone and DMSO. The solubility of chartreusin in DMSO is approximately 10 mg/ml. Chartreusin is also slightly soluble in methanol.

Description

Chartreusin is an antibiotic originally isolated from S. chartreusis with diverse biological activities.¹ It inhibits growth of S. aureus, B. subtilis, M. luteus, M. flavus, B. fragilis, C. difficile, C. perfringens, and *P. acnes* (MICs = 0.4-12.5 μ g/ml).² Chartreusin binds to DNA and induces electrophoretic shifts in both supercoiled and nicked plasmid DNA.³ It also inhibits strand-passing activity of topoisomerase II in a P4 unknotting assay. Chartreusin inhibits protein synthesis in chick embryo fibroblasts (CEFs) and mouse fibroblast 3T6 cells (IC₅₀s = 7 and 70 μ M, respectively).⁴ It is cytotoxic to human lung carcinoma A549 cells in vitro (IC₅₀ = 95 nM) and increases median survival in P388 leukemia and B16 melanoma mouse tumor models when administered at a dose of 10 mg/kg per day.^{2,3}

References

- 1. Leach, B.E., Calhoun, K.M., Johnson, L.E., et al. Chartreusin, a new antibiotic produced by Streptomyces chartreusis, a new species. J. Am. Chem. Soc. 75(16), 4011-4012 (1953).
- 2. Konishi, M., Sugawara, K., Kofu, F., et al. Elsamicins, new antitumor antibiotics related to chartreusin. I. Production, isolation, characterization and antitumor activity. J. Antibiot. (Tokyo) 39(6), 784-791 (1986).
- 3. Lorico, A. and Long, B.H. Biochemical characterisation of elsamicin and other coumarin-related antitumour agents as potent inhibitors of human topoisomerase II. Eur. J. Cancer 29A(14), 1985-1991 (1993).
- 4. Contreras, A., Vazquez, D., and Carrasco, L. Inhibition, by selected antibiotics, of protein synthesis in cells growing in tissue cultures. J. Antibiot. (Tokyo) 31(6), 598-602 (1978).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/04/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM